TABLE 2.
Characteristics of and LDA results for HHV-8 PCR-negative subjects
| Group | KS status | CD4 count in cells/μl (%) | HIV load (no. of copies/ml) | HIV treatmenta | KS treatment | Antiherpes treatment | No. of HHV-8 genomes/106 PBMCb | HHV-8 antibody titer |
|---|---|---|---|---|---|---|---|---|
| KS subjects | ||||||||
| 1 | Cutaneous (progressing) | 613 (47) | 565 | d4T, 3TC, NVR | Doxorubicin | No | <0.21 | 6,400 |
| <0.15c | ||||||||
| 2 | Inactive unresolved cutaneous KS | 93 (7) | 1,266 | NFV, Combivir | No | ACV | <0.93 >0.58d | 3,200 |
| 3 | Resolved KS, no current lesions | 435 (12) | 226 | NFV, combivir | No | No | <1.00 | 400 |
| Subjects at risk for KS | ||||||||
| 4 | No KS | 558 (25) | 719 | NFV, NVR, Combivir | No | No | <1.20 0.34c | 400 |
| 5 | No KS | 201 (15) | 1.1 × 104 | ddl, d4T, NFV, NVR | No | No | <0.67 | 400 |
| 6 | No KS | 434 (18) | Undetectable | Combivir, EFV | No | No | <0.37 | 6,400 |
a
d4T, stavudine; 3TC, lamivudine; NVR, nevirapine; NFV, nelfinavir; combivir, zidovudine and lamivudine; ACV, acyclovir; ddl, didanosine; EFV, efavirenz.
b
The less than signs indicate the upper bound of virus load in individuals in whom virus DNA was not detected.
c
Result when the number of replicates was increased from 12 to 22, which led to a positive result for subject 4.
d
Result when the number of replicates was increased from 12 to 17.